Constrained use of CCR5 on CD4+lymphocytes by R5X4 HIV-1: Efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry

被引:8
|
作者
Loftin, Lamorris M. [1 ,2 ]
Kienzle, Martha F. [1 ]
Yi, Yanjie [1 ]
Lee, Benhur [3 ]
Lee, Fang-Hua [2 ]
Gray, Lachlan [4 ]
Gorry, Paul R. [4 ]
Collman, Ronald G. [1 ]
机构
[1] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
[4] Ctr Virol, Burnet Inst, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
R5X4; HIV-1; CD4+lymphocytes; CCR5; Coreceptor use; Viral entry; tropism; IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCYTE-DERIVED MACROPHAGES; CENTRAL-NERVOUS-SYSTEM; HUMAN LYMPHOID-TISSUE; DUAL-TROPIC HIV-1; CORECEPTOR USAGE; V3; LOOP; BIOLOGICAL PHENOTYPE; IN-VITRO; CCR5-DELTA-32; ALLELE;
D O I
10.1016/j.virol.2010.03.009
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
R5X4 HIV-1 has impaired utilization of CCR5 on primary CD4+ lymphocytes but the mechanisms responsible are not well defined. Using a panel of diverse R5X4 Envs we identified a spectrum of CCR5 use on CD4+ lymphocytes. Greater lymphocyte CCR5 use correlated with relative resistance to CCR5 mAbs and small molecule antagonists. Increasing CCR5 expression on lymphocytes increased the proportion of entry mediated by CCR5 for all R5X4 isolates except 89.6. In cell lines with regulated CCR5 expression, strains with greater lymphocyte CCR5 use better exploited limiting levels of CCR5. Introduction of an R306S mutation in the 89.6 V3 domain enhanced its utilization of CCR5 at low levels and switched its preference to CCR5 for lymphocyte entry. Thus, the degree to which R5X4 HIV-1 use primary lymphocyte CCR5 is determined by low CCR5 expression coupled with variations in the efficiency of Env-CCR5 interactions, which is in part governed by V3 sequences. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:135 / 148
页数:14
相关论文
共 50 条
  • [1] Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry
    Nahabedian, John
    Sharma, Amit
    Kaczmarek, Maryska E.
    Wilkerson, Greg K.
    Sawyer, Sara L.
    Overbaugh, Julie
    VIROLOGY, 2017, 512 : 180 - 186
  • [2] Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32
    Benkirane, M
    Jin, DY
    Chun, RF
    Koup, RA
    Jeang, KT
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) : 30603 - 30606
  • [3] CCR5 antagonist-resistant HIV-1 entry kinetics as a function of CD4 and CCR5 surface expression
    Putcharoen, O.
    Lee, S-H
    Henrich, T. J.
    Vanichanan, J.
    Kuritzkes, D. R.
    Tsibris, A. M. N.
    ANTIVIRAL THERAPY, 2011, 16 : A64 - A64
  • [4] Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication
    Gong, WH
    Howard, OMZ
    Turpin, JA
    Grimm, MC
    Ueda, H
    Gray, PW
    Raport, CJ
    Oppenheim, JJ
    Wang, JM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (08) : 4289 - 4292
  • [5] Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
    Berro, Reem
    Sanders, Rogier W.
    Lu, Min
    Klasse, Per J.
    Moore, John P.
    PLOS PATHOGENS, 2009, 5 (08)
  • [6] Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors
    Henrich, T. J.
    Lewine, N.
    Lee, S-H
    Rao, S.
    Berro, R.
    Greaves, W.
    Gulick, R.
    Tsibris, A.
    Moore, J.
    Kuritzkes, D.
    ANTIVIRAL THERAPY, 2011, 16 : A59 - A59
  • [7] HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
    Pugach, Pavel
    Marozsan, Andre J.
    Ketas, Thomas J.
    Landes, Elissa L.
    Moore, John P.
    Kuhmann, Shawn E.
    VIROLOGY, 2007, 361 (01) : 212 - 228
  • [8] Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists
    Henrich, Timothy J.
    Lewine, Nicolas R. P.
    Lee, Sun-Hee
    Rao, Suhas S. P.
    Berro, Reem
    Gulick, Roy M.
    Moore, John P.
    Tsibris, Athe M. N.
    Kuritzkes, Daniel R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) : 1931 - 1935
  • [9] CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
    Salkowitz, JR
    Bruse, SE
    Meyerson, H
    Valdez, H
    Mosier, DE
    Harding, CV
    Zimmerman, PA
    Lederman, MM
    CLINICAL IMMUNOLOGY, 2003, 108 (03) : 234 - 240
  • [10] HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4+ T Cells
    Pfaff, Jennifer M.
    Wilen, Craig B.
    Harrison, Jessamina E.
    Demarest, James F.
    Lee, Benhur
    Doms, Robert W.
    Tilton, John C.
    JOURNAL OF VIROLOGY, 2010, 84 (13) : 6505 - 6514